Pathology Technology Australia and InGeNA Limited welcome the move to legislate a total ban on the use of genomic data by Life Insurers to discriminate against individuals.
“If Australia is to maintain equitable, timely, and economically sustainable healthcare for all Australians we will need to pivot towards more predictive, preventative, and personalised methods of healthcare delivery. Genetic testing will be foundational in this approach, thus the prevailing infrastructure must also evolve.” Dean Whiting, CEO PTA.
This issue has brought together industry leaders and patient advocacy groups in a collective effort to address the significant barriers facing individuals considering genetic testing.
The collaboration between these groups highlights the shared commitment to improving healthcare access and ensuring that Australians are empowered to make informed decisions about their health without fear of discrimination.
We would also like to acknowledge the recommendations report by Dr. Jane Tiller (PhD) Tiller and Professor Paul Lacaze and the tireless advocacy of Dr Tiller on this issue.
Read our full joint statement here